NASDAQ · MNKD
MannKind Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for MNKD: Nov 4, 2026
MannKind Corporation Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.08. The reported EPS for the same quarter last year was $0.03.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.08 | $-0.06 | $-0.10 | 2 |
| Dec 2026 | $-0.04 | $-0.03 | $-0.06 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Zacks- MarketBeat · Oct 20, 4:03 PM EDTMannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX GrowthMannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestina
- MarketBeat · Sep 17, 6:02 PM EDTMannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains MomentumMannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX
- RTTNews · Sep 9, 7:06 AM EDTMannKind, Rose Pharma Team Up On Rapid-Acting Inhaled GLP-1(RTTNews) – MannKind Corporation (MNKD) and Rose Pharma Inc. have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere, an investigational rapid-acting, short-duration inhaled GLP-1 receptor agonist for weight management.
- Zacks · Aug 28, 9:22 AM EDTFDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAHUTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
- Zacks · Aug 6, 9:03 AM EDTUnited Therapeutics Q2 Earnings Beat Estimates, Revenues Miss MarkUTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
- MarketBeat · Aug 5, 11:03 PM EDTMannKind Q2 Earnings Call HighlightsMannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs. The company recorded a
- Zacks · Aug 5, 7:00 PM EDTCompared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key MetricsThe headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks · Aug 5, 6:10 PM EDTMannKind (MNKD) Reports Q2 Loss, Beats Revenue EstimatesMannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Jul 29, 7:04 PM EDTMannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 UnderwayMannKind (NASDAQ:MNKD) reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability. The comp
- RTTNews · Jul 29, 7:21 AM EDTMannKind's Nintedanib DPI Shows Favorable Safety In IPF Patients(RTTNews) – MannKind Corporation (MNKD) announced positive topline results from its Phase 1b INFLO-1 study of nintedanib dry powder inhalation (DPI) in idiopathic pulmonary fibrosis (IPF), meeting its primary objective of demonstrating safety and tolerability.
- MarketBeat · Jul 24, 11:03 AM EDTMannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPEMannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagn
- RTTNews · Jul 24, 10:27 AM EDTMannkind Wins FDA Nod For Furoscix ReadyFlow, Announces $50 Mln Private Placement(RTTNews) – MannKind Corp. (MNKD), a biopharmaceutical company, announced Friday that it received U.S. FDA approval for Furoscix ReadyFlow to treat edema in adults with heart failure or chronic kidney disease.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for MannKind Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.